Obrixtamig clinical trials
Obrixtamig is named as an intervention in 12 current clinical trials in our Germany, USA, France, Spain, Japan, Belgium, Netherlands, Poland, UK, China, Australia, Sweden, Switzerland, Austria, Portugal, South Korea, Taiwan, Italy, Czechia, Norway, Canada, Brazil, Mexico, Ireland, Turkey, Singapore, Denmark and Israel registers. 6 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Boehringer Ingelheim. The most-studied condition is Small Cell Lung Carcinoma (SCLC). The EU clinical trials register (CTIS) separately lists 5 authorised or ongoing trials, 1 with a site in Ireland.
Where Obrixtamig is approved
All regulators →- 2 EU orphan designations, most recently for treatment of extrapulmonary neuroendocrine carcinoma (21 Aug 2024, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Obrixtamig works
All drug targets →- Small cell lung carcinomaPhase 3
- Neuroendocrine carcinomaPhase 2
- Pulmonary large cell neuroendocrine carcinomaPhase 2
- Brain neoplasmPhase 1
- GliomaPhase 1
- Neuroendocrine neoplasmPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068151, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Obrixtamig
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Obrixtamig
12 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Obrixtamig in the EU trials register (CTIS)
5 trials · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Obrixtamig. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Conditions studied with Obrixtamig
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Small Cell Lung Carcinoma (SCLC) | 4 |
| Neuroendocrine Neoplasms | 4 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 1 |
| Small Cell Lung Cancer | 1 |
| Large Cell Neuroendocrine Lung Carcinoma | 1 |
| Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology | 1 |
| Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology | 1 |
| Extrapulmonary Neuroendocrine Cancer (epNEC) | 1 |
| Small Cell Lung Carcinoma | 1 |
| Extra-pulmonary Neuroendocrine Carcinoma | 1 |
| Extensive-stage Small Cell Lung Carcinoma | 1 |
| Advanced Small Cell Lung Cancer | 1 |
| Glioma | 1 |
| Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Boehringer Ingelheim | 12 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Obrixtamig trials
How many clinical trials are testing Obrixtamig?
12 current trials in our Germany, USA, France, Spain, Japan, Belgium, Netherlands, Poland, UK, China, Australia, Sweden, Switzerland, Austria, Portugal, South Korea, Taiwan, Italy, Czechia, Norway, Canada, Brazil, Mexico, Ireland, Turkey, Singapore, Denmark and Israel registers name Obrixtamig (also registered as BI 764532) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Obrixtamig trials recruiting patients?
Yes. 6 of the 12 trials are recruiting: 5 with sites in Germany, 5 with sites in USA, 4 with sites in France, 5 with sites in Spain, 4 with sites in Japan, 4 with sites in Belgium, 5 with sites in Netherlands, 3 with sites in Poland, 3 with sites in UK, 4 with sites in China, 3 with sites in Australia, 2 with sites in Sweden, 2 with sites in Switzerland, 3 with sites in Austria, 3 with sites in Portugal, 3 with sites in South Korea, 3 with sites in Taiwan, 2 with sites in Italy, 2 with sites in Czechia, 2 with sites in Norway, 2 with sites in Canada, 2 with sites in Brazil, 2 with sites in Mexico, 1 with sites in Ireland, 1 with sites in Turkey, 1 with sites in Singapore, 1 with sites in Denmark and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Obrixtamig clinical trials?
The lead sponsor is Boehringer Ingelheim. The number in brackets is how many trials each organisation leads.
Are there Obrixtamig clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Obrixtamig works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Obrixtamig works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Obrixtamig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.